Bausch Health Companies Inc. (BHC): Price and Financial Metrics


Bausch Health Companies Inc. (BHC): $6.82

0.06 (+0.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BHC POWR Grades

  • BHC scores best on the Value dimension, with a Value rank ahead of 97.94% of US stocks.
  • The strongest trend for BHC is in Quality, which has been heading up over the past 179 days.
  • BHC ranks lowest in Sentiment; there it ranks in the 4th percentile.

BHC Stock Summary

  • BHC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.08 -- higher than only 1.2% of US-listed equities with positive expected earnings growth.
  • BHC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 0.44% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, BAUSCH HEALTH COMPANIES INC is reporting a growth rate of 12,278.57%; that's higher than 99.85% of US stocks.
  • If you're looking for stocks that are quantitatively similar to BAUSCH HEALTH COMPANIES INC, a group of peers worth examining would be MULN, CCLP, AHT, ATUS, and SFT.
  • Visit BHC's SEC page to see the company's official filings. To visit the company's web site, go to www.bauschhealth.com.

BHC Valuation Summary

  • BHC's EV/EBIT ratio is 13.4; this is 68.55% higher than that of the median Healthcare stock.
  • BHC's price/sales ratio has moved down 8.6 over the prior 243 months.

Below are key valuation metrics over time for BHC.

Stock Date P/S P/B P/E EV/EBIT
BHC 2022-11-22 0.3 -4.8 9.9 13.4
BHC 2022-11-21 0.3 -4.8 9.9 13.4
BHC 2022-11-18 0.3 -5.2 10.8 13.5
BHC 2022-11-17 0.3 -5.2 10.8 13.5
BHC 2022-11-16 0.3 -4.8 9.9 13.4
BHC 2022-11-15 0.3 -4.9 10.2 13.5

BHC Growth Metrics

    Its 5 year revenue growth rate is now at -11.13%.
  • Its year over year cash and equivalents growth rate is now at 29.95%.
  • Its 5 year price growth rate is now at 16.78%.
Over the past 15 months, BHC's revenue has gone down $351,000,000.

The table below shows BHC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8,127 -1,179 254
2022-06-30 8,192 648 43
2022-03-31 8,325 920 -407
2021-12-31 8,434 1,426 -948
2021-09-30 8,451 1,796 -1,170
2021-06-30 8,478 1,488 -1,287

BHC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BHC has a Quality Grade of C, ranking ahead of 53.93% of graded US stocks.
  • BHC's asset turnover comes in at 0.276 -- ranking 162nd of 680 Pharmaceutical Products stocks.
  • CCXI, NBY, and LLY are the stocks whose asset turnover ratios are most correlated with BHC.

The table below shows BHC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.276 0.714 -0.004
2021-03-31 0.259 0.714 0.006
2020-12-31 0.255 0.720 0.022
2020-09-30 0.250 0.721 -0.017
2020-06-30 0.252 0.725 -0.021
2020-03-31 0.265 0.729 -0.011

BHC Price Target

For more insight on analysts targets of BHC, see our BHC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.08 Average Broker Recommendation 1.62 (Moderate Buy)

BHC Stock Price Chart Interactive Chart >

Price chart for BHC

BHC Price/Volume Stats

Current price $6.82 52-week high $28.35
Prev. close $6.76 52-week low $4.00
Day low $6.67 Volume 4,202,000
Day high $6.91 Avg. volume 6,391,805
50-day MA $6.95 Dividend yield N/A
200-day MA $11.83 Market Cap 2.47B

Bausch Health Companies Inc. (BHC) Company Bio


Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.


BHC Latest News Stream


Event/Time News Detail
Loading, please wait...

BHC Latest Social Stream


Loading social stream, please wait...

View Full BHC Social Stream

Latest BHC News From Around the Web

Below are the latest news stories about BAUSCH HEALTH COMPANIES INC that investors may wish to consider to help them evaluate BHC as an investment opportunity.

Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C.

Yahoo | November 29, 2022

Citing recent SCOTUS decision, appeals court overturns millions of dollars in arbitration awards won by DST employees

According to Ken McClain, one of the attorneys representing participants in the profit-sharing plan dispute, the federal court in Kansas City had confirmed about $36 million in arbitration awards before the appeals court ruling was released Monday.

Yahoo | November 29, 2022

Lupin, BSE, NBCC, Filatex Fashions in focus

Lupin: Lupin announced that its wholly owned subsidiary in Brazil, MedQuica Indtria Farmactica (MedQuica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indtria ica Ltda., a subsidiary of Bausch Health Companies Inc.

Business Standard | November 28, 2022

Lupin’s Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch Health

Mumbai, Sao Paulo, November 28, 2022: Global pharma major, Lupin Limited (Lupin) announced today that its wholly owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.

Lupin | November 28, 2022

Is There An Opportunity With Bausch + Lomb Corporation's (NYSE:BLCO) 45% Undervaluation?

How far off is Bausch + Lomb Corporation ( NYSE:BLCO ) from its intrinsic value? Using the most recent financial data...

Yahoo | November 26, 2022

Read More 'BHC' Stories Here

BHC Price Returns

1-mo 4.92%
3-mo 3.49%
6-mo -25.22%
1-year -71.39%
3-year -75.85%
5-year -60.46%
YTD -75.30%
2021 32.74%
2020 -30.48%
2019 61.99%
2018 -11.12%
2017 43.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9417 seconds.